EPHB4 and malignant mesothelioma: As summarized by the effect displayed in Fig. 2, the neutralizing IGF-II antibody treatment was able to inhibit EphB4 protein expression between 54 and 82 percent among the malignant mesothelioma cell lines studies (Fig. 2a, b upper row).